Publicaciones en colaboración con investigadores/as de Hospital del Mar (11)

2021

  1. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

2020

  1. Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients

    Cancer Treatment Reviews, Vol. 83

  2. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

  3. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)

    Breast Cancer Research and Treatment, Vol. 184, Núm. 2, pp. 469-479

2019

  1. SEOM clinical guidelines in early stage breast cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 18-30

2018

  1. Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii91-viii92

  2. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

    The Lancet Oncology, Vol. 19, Núm. 6, pp. 812-824

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2015

  1. SEOM clinical guidelines in early-stage breast cancer 2015

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 939-945

2010

  1. SEOM clinical guidelines for the treatment of early breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 711-718

2006

  1. Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: Efficacy and correlation with HER2 extracellular domain

    Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 896-902